{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-020667","form_type":"8-K","ticker":"PVLA","cik":"0001583648","company_name":"PALVELLA THERAPEUTICS, INC.","filed_at":"2026-02-26T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.535429+00:00","generated_at":"2026-05-15T23:36:40.278853+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Palvella Therapeutics raises ~$187.3M in public offering of 1.6M shares at $125/sh","bullets":["Underwriting agreement with TD Securities, Cantor Fitzgerald, and Stifel for 1,600,000 shares at $125.00 each.","Underwriters have 30-day option to purchase up to an additional 240,000 shares at same price.","Net proceeds estimated at $187.3M after underwriting discounts and expenses.","Proceeds to support QTORIN rapamycin and pitavastatin programs, R&D, and working capital.","Closing expected on or about February 27, 2026, subject to customary conditions."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-020667","json":"https://secwatch.observer/filing/0001104659-26-020667.json","markdown":"https://secwatch.observer/filing/0001104659-26-020667.md","text":"https://secwatch.observer/filing/0001104659-26-020667.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1583648/000110465926020667/0001104659-26-020667-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1583648/000110465926020667/tm2534019d6_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T23:36:40.278853+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e5a62802c22b2ce60cedb7d9531fe1e20abe329b","claim":"PALVELLA THERAPEUTICS, INC. entered into Underwriting Agreement with TD Securities (USA) LLC, Cantor Fitzgerald & Co. and Stifel, Nicolaus & Company, Incorporated valued at approximately $187.3 million (effective 2026-02-25).","evidence_excerpt":"On February 25, 2026, Palvella Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with TD Securities (USA) LLC, Cantor Fitzgerald & Co. and Stifel, Nicolaus & Company, Incorporated, as representatives (the “Representatives”) of the underwriters listed in Schedule A thereto (the “Underwriters”), pursuant to which the Company agreed to issue and sell an aggregate of 1,600,000 shares (the “Firm Shares”) of its common stock, par value $0.001 per share (the “Common Stock”), at a price to the public of $125.00 (the “Offering”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1583648/000110465926020667/0001104659-26-020667-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"underwriting"},{"label":"Counterparty","value":"TD Securities (USA) LLC, Cantor Fitzgerald & Co. and Stifel, Nicolaus & Company, Incorporated"},{"label":"Value","value":"approximately $187.3 million"},{"label":"Effective","value":"2026-02-25"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}